3.71
-0.152(-3.93%)
Currency In USD
| Previous Close | 3.87 |
| Open | 3.84 |
| Day High | 3.88 |
| Day Low | 3.71 |
| 52-Week High | 4.69 |
| 52-Week Low | 2.2 |
| Volume | 32,715 |
| Average Volume | 62,779 |
| Market Cap | 315.85M |
| PE | -7.74 |
| EPS | -0.48 |
| Moving Average 50 Days | 4.01 |
| Moving Average 200 Days | 3.21 |
| Change | -0.15 |
If you invested $1000 in Alpha Tau Medical Ltd. (DRTS) since IPO date, it would be worth $367.72 as of November 17, 2025 at a share price of $3.714. Whereas If you bought $1000 worth of Alpha Tau Medical Ltd. (DRTS) shares 3 years ago, it would be worth $935.52 as of November 17, 2025 at a share price of $3.714.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 11, 2025 1:30 PM GMT
JERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will particip
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
GlobeNewswire Inc.
Oct 21, 2025 12:30 PM GMT
- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation - - License paves way for i
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
GlobeNewswire Inc.
Sep 02, 2025 12:30 PM GMT
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or